RecruitingPhase 3NCT06868277
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Sponsor: AstraZeneca
Fountain Hill, PA · Kittanning, PA · Philadelphia, PA · +36 more sites